Regeneron Pharmaceuticals, Inc. (REGN)
REGN Stock Price Chart
Explore Regeneron Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze REGN price movements and trends.
REGN Company Profile
Discover essential business fundamentals and corporate details for Regeneron Pharmaceuticals, Inc. (REGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Apr 1991
Employees
15.16k
Website
https://www.regeneron.comCEO
Leonard S. Schleifer
Description
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
REGN Financial Timeline
Browse a chronological timeline of Regeneron Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $10.36, while revenue estimate is $3.81bn.
Dividend declared on 20 May 2026
A dividend of $0.94 per share was announced, adjusted to $0.94. The dividend was paid on 4 Jun 2026.
Earnings released on 29 Apr 2026
EPS came in at $9.47 surpassing the estimated $8.91 by +6.29%, while revenue for the quarter reached $3.61bn , beating expectations by +3.59%.
Dividend declared on 20 Feb 2026
A dividend of $0.94 per share was announced, adjusted to $0.94. The dividend was paid on 5 Mar 2026.
Earnings released on 30 Jan 2026
EPS came in at $11.44 surpassing the estimated $10.74 by +6.52%, while revenue for the quarter reached $3.88bn , beating expectations by +1.93%.
Dividend declared on 20 Nov 2025
A dividend of $0.88 per share was announced, adjusted to $0.88. The dividend was paid on 5 Dec 2025.
Earnings released on 28 Oct 2025
EPS came in at $11.83 surpassing the estimated $9.65 by +22.59%, while revenue for the quarter reached $3.75bn , beating expectations by +4.51%.
Dividend declared on 18 Aug 2025
A dividend of $0.88 per share was announced, adjusted to $0.88. The dividend was paid on 3 Sept 2025.
Earnings released on 1 Aug 2025
EPS came in at $12.89 surpassing the estimated $8.43 by +52.91%, while revenue for the quarter reached $3.68bn , beating expectations by +11.78%.
Dividend declared on 20 May 2025
A dividend of $0.88 per share was announced, adjusted to $0.88. The dividend was paid on 6 Jun 2025.
Earnings released on 29 Apr 2025
EPS came in at $8.22 falling short of the estimated $8.62 by -4.64%, while revenue for the quarter reached $3.03bn , missing expectations by -6.75%.
Dividend declared on 20 Feb 2025
A dividend of $0.88 per share was announced, adjusted to $0.88. The dividend was paid on 20 Mar 2025.
Earnings released on 4 Feb 2025
EPS came in at $12.07 surpassing the estimated $11.21 by +7.67%, while revenue for the quarter reached $3.79bn , beating expectations by +1.25%.
Earnings released on 31 Oct 2024
EPS came in at $12.46 surpassing the estimated $11.69 by +6.59%, while revenue for the quarter reached $3.72bn , beating expectations by +1.25%.
Earnings released on 1 Aug 2024
EPS came in at $11.56 surpassing the estimated $10.61 by +8.95%, while revenue for the quarter reached $3.55bn , beating expectations by +4.83%.
Earnings released on 2 May 2024
EPS came in at $9.55 falling short of the estimated $10.17 by -6.10%, while revenue for the quarter reached $3.15bn , missing expectations by -2.49%.
Earnings released on 2 Feb 2024
EPS came in at $11.86 surpassing the estimated $10.73 by +10.53%, while revenue for the quarter reached $3.43bn , beating expectations by +4.25%.
Earnings released on 2 Nov 2023
EPS came in at $11.59 surpassing the estimated $10.72 by +8.12%, while revenue for the quarter reached $3.36bn , beating expectations by +4.40%.
Earnings released on 3 Aug 2023
EPS came in at $10.24 surpassing the estimated $9.84 by +4.07%, while revenue for the quarter reached $3.16bn , beating expectations by +4.68%.
Earnings released on 4 May 2023
EPS came in at $10.09 surpassing the estimated $9.25 by +9.08%, while revenue for the quarter reached $3.16bn , beating expectations by +5.39%.
Earnings released on 3 Feb 2023
EPS came in at $12.56 surpassing the estimated $10.03 by +25.22%, while revenue for the quarter reached $3.41bn , beating expectations by +9.27%.
Earnings released on 3 Nov 2022
EPS came in at $11.14 surpassing the estimated $9.48 by +17.51%, while revenue for the quarter reached $2.94bn , beating expectations by +0.71%.
Earnings released on 3 Aug 2022
EPS came in at $9.77 surpassing the estimated $8.53 by +14.54%, while revenue for the quarter reached $2.86bn , beating expectations by +2.25%.
Earnings released on 4 May 2022
EPS came in at $8.93 falling short of the estimated $9.74 by -8.32%, while revenue for the quarter reached $2.97bn , beating expectations by +10.22%.
Earnings released on 4 Feb 2022
EPS came in at $21.32 surpassing the estimated $18.35 by +16.19%, while revenue for the quarter reached $4.95bn , beating expectations by +8.53%.
Earnings released on 4 Nov 2021
EPS came in at $14.37 surpassing the estimated $10.10 by +42.28%, while revenue for the quarter reached $3.45bn , beating expectations by +28.54%.
Earnings released on 5 Aug 2021
EPS came in at $25.80 surpassing the estimated $17.53 by +47.18%, while revenue for the quarter reached $5.14bn , beating expectations by +31.19%.
REGN Stock Performance
Access detailed REGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
